Epigenetic reprogramming of monocytes in patients with coronary atherosclerosis

Epigenetic reprogramming of monocytes in patients with coronary atherosclerosis - Trained immunity in atherosclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38690

Enrollment

Registered

2013-11-05

Start date

2014-10-30

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients (male/female), aged >18 years, admitted to the acute coronary unit of the CWZ hospital for evaluation of chest pain. Inclusion criteria: - No coronary atherosclerosis (TPS6): then participation in the patient.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Acute coronary syndrome (ST-segment elevation or depression and elevated plasma troponin levels) - Use of statins or thrombocyte aggregation inhibitors (since these drugs have been shown to modulate epigenetic changes in in vitro studies). Of course, these drugs can be given after blood sampling if clinically indicated. - Signs or symptoms of a current infection (fever, chills) - Auto-immune diseases (such as rheumatoid arthritis)

Design outcomes

Primary

Measure	Time frame
Blood will be drawn immediately upon inclusion for isolation of monocytes. The primary endpoint is H3K4 trimethylation in the promoter region of inflammatory cytokines.	—

Secondary

Measure	Time frame
Secondary endpoints is the cytokine release in response to stimulation with TLR agonists and foam cell formation	—

Countries

Netherlands

Outcome results